Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2015 Sep 17;24(12):1873–1881. doi: 10.1158/1055-9965.EPI-15-0553

Figure 2. Mutational signatures determined by NMF.

Figure 2

Results are shown for urothelial carcinoma samples sequenced on HiSeq2500. A) Contribution of each mutation type to signatures of AA, age/CpG and APOBEC. The x-axis represents the trinucleotide sequence contexts, with the 5’-flank base in the first row and the 3’-flank in the second. B) Contributions of the studied urothelial tumors to the individual signatures shown in A. C) Correlation between NMF-identified EN sample (EN UC) signatures and previously described COSMIC Signatures 1, 2/13 and 22 (22), signature 22 identified in Taiwan UTUC samples (8, 21), and signature 22 AA Exp, modeled experimentally in vitro (32).